Skip to main content

“Unresectable” Vulval Cancers: Is Neoadjuvant Chemotherapy the Way Forward?

Current Oncology Reports volume 15, pages 573–580 (2013)Cite this article

Abstract

Squamous cell carcinoma of the vulva is an uncommon gynaecological malignancy, but the incidence is increasing. A significant proportion of patients present with locally advanced disease, and management can prove challenging because of the size and/or location of the tumour. Surgery forms the mainstay of treatment, but the role of neoadjuvant therapy in minimizing morbidity is under investigation. Although chemotherapy alone has been largely neglected in favour of chemoradiotherapy, concerns about the toxicity of trimodality therapy and suboptimal results, particularly in node-positive patients, have led to renewed interest in neoadjuvant chemotherapy (NACT). A review of the available literature illustrates that NACT can produce dramatic responses, but operability rates and overall survival differ widely. The effect is dependent on as yet unidentified factors, although we speculate that age and tumour biology are important. Further work is required to delineate the optimal NACT regimen and the patient population(s) most likely to benefit from this practice.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Center MM, Ward E, et al. Cancer occurrence. Methods Mol Biol. 2009;471:3–29.

    PubMed  Article  Google Scholar 

  2. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013;62:161–75.

    PubMed  Article  Google Scholar 

  3. Taussig FJ. Cancer of the vulva: an analysis of 155 cases. Am J Obstet Gynecol. 1940;40:764–9.

    Google Scholar 

  4. Way S. Carcinoma of the vulva. Am J Obstet Gynecol. 1960;79:692–7.

    PubMed  CAS  Google Scholar 

  5. De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. Cancer. 2002;95:2331–8.

    PubMed  Article  Google Scholar 

  6. Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990;38:309–14.

    PubMed  Article  CAS  Google Scholar 

  7. Burger MP, Hollema H, Emanuels AG, et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57:327–34.

    PubMed  Article  CAS  Google Scholar 

  8. Burke TW, Levenback C, Coleman RL, et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995;57:215–20.

    PubMed  Article  CAS  Google Scholar 

  9. Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986;68:733–40.

    PubMed  CAS  Google Scholar 

  10. Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol. 1993;49:279–83.

    PubMed  Article  CAS  Google Scholar 

  11. Ballon SC, Lamb EJ. Separate inguinal incisions in the treatment of carcinoma of the vulva. Surg Gynecol Obstet. 1975;140:81–4.

    PubMed  CAS  Google Scholar 

  12. Byron SC, Lamb EJ, Yonemoto RH, Kase S. Radical inguinal node dissection in the treatment of cancer. Surg Gynecol Obstet. 1962;114:401–8.

    Google Scholar 

  13. Moore DH. Reflections on vulvar tumors, lymphatic drainage, and sentinel lymph node biopsy. Gynecol Oncol. 2013;128:153–4.

    PubMed  Article  Google Scholar 

  14. Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:79–85.

    PubMed  Article  CAS  Google Scholar 

  15. Maggioni A, Roviglione G, Landoni F, et al. Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan. Gynecol Oncol. 2009;114:64–8.

    PubMed  Article  Google Scholar 

  16. Forner DM, Lampe B. Exenteration in the treatment of stage III/IV vulvar cancer. Gynecol Oncol. 2012;124:87–91.

    PubMed  Article  Google Scholar 

  17. Baiocchi G, Guimaraes GC, Rosa Oliveira RA, et al. Prognostic factors in pelvic exenteration for gynecological malignancies. Eur J Surg Oncol. 2012;38:948–54.

    PubMed  Article  CAS  Google Scholar 

  18. Gadducci A, Tana R, Barsotti C, et al. Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol. 2012;83:71–83.

    PubMed  Article  Google Scholar 

  19. Gadducci A, Ferrero A, Tana R, et al. Prognostic value of lymph node status and number of removed nodes in patients with squamous cell carcinoma of the vulva treated with modified radical vulvectomy and inguinal-femoral lymphadenectomy. Eur J Gynaecol Oncol. 2012;33:640–3.

    PubMed  CAS  Google Scholar 

  20. Boronow RC, Hickman BT, Reagan MT, et al. Combined therapy as an alternative to exenteration for locally advanced vulvovaginal cancer. II. Results, complications, and dosimetric and surgical considerations. Am J Clin Oncol. 1987;10:171–81.

    PubMed  Article  CAS  Google Scholar 

  21. Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol. 1996;61:321–7.

    PubMed  Article  CAS  Google Scholar 

  22. Eifel PJ, Morris M, Burke TW, et al. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 1995;59:51–6.

    PubMed  Article  CAS  Google Scholar 

  23. Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 2000;48:1007–13.

    PubMed  Article  CAS  Google Scholar 

  24. Scheistroen M, Trope C. Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva. Acta Oncol. 1993;32:657–61.

    PubMed  Article  CAS  Google Scholar 

  25. van Doorn HC, Ansink A, Verhaar-Langereis M, et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev. 2006;3, CD003752.

    PubMed  Google Scholar 

  26. • Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev. 2011;(4):CD003752. This updated review of neoadjuvant chemoradiotherapy suggests no improvement in survival compared with surgery alone.

  27. Maneo A, Landoni, F, Colombo, A, et al. Randomised study between neoadjuvant chemoradiotherapy and primary surgery for the treatment of advanced vulval cancer. Int J Gyn Cancer. 2003;13 (Suppl 1):abstr PL39.

  28. Thomas GM, Dembo AJ, Bryson SC, et al. Changing concepts in the management of vulvar cancer. Gynecol Oncol. 1991;42:9–21.

    PubMed  Article  CAS  Google Scholar 

  29. • Tans L, Ansink AC, van Rooij PH, et al. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol. 2011;34:22–6. This is a recent review of primary chemoradiotherapy in locally advanced vulval cancer.

    PubMed  Article  Google Scholar 

  30. Mulayim N, Foster Silver D, Schwartz PE, et al. Chemoradiation with 5-fluorouracil and mitomycin C in the treatment of vulvar squamous cell carcinoma. Gynecol Oncol. 2004;93:659–66.

    PubMed  Article  CAS  Google Scholar 

  31. Landrum LM, Skaggs V, Gould N, et al. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol. 2008;108:584–90.

    PubMed  Article  Google Scholar 

  32. Bloemers MC, Portelance L, Ruo R, et al. A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy. Med Dosim. 2012;37:310–3.

    PubMed  Article  Google Scholar 

  33. Muss HB, Bundy BN, Christopherson WA. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1989;12:142–4.

    PubMed  Article  CAS  Google Scholar 

  34. Slayton RE, Blessing JA, Beecham J, et al. Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group study. Cancer Treat Rep. 1987;71:869–70.

    PubMed  CAS  Google Scholar 

  35. Gerszten K, Selvaraj RN, Kelley J, et al. Preoperative chemoradiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 2005;99:640–4.

    PubMed  Article  Google Scholar 

  36. Deppe G, Bruckner HW, Cohen CJ. Adriamycin treatment of advanced vulvar carcinoma. Obstet Gynecol. 1977;50:13s–4.

    PubMed  CAS  Google Scholar 

  37. Deppe G, Cohen CJ, Bruckner HW. Chemotherapy of squamous cell carcinoma of the vulva: a review. Gynecol Oncol. 1979;7:345–8.

    PubMed  Article  CAS  Google Scholar 

  38. Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer–Gynaecological Cancer Group). Ann Oncol. 2009;20:1511–6.

    PubMed  Article  CAS  Google Scholar 

  39. Jaakkola M, Rantanen V, Grenman S, et al. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro. Anticancer Res. 1997;17:939–43.

    PubMed  CAS  Google Scholar 

  40. Conroy JF, Lewis GC, Brady LW, et al. Low dose bleomycin and methotrexate in cervical cancer. Cancer. 1976;37:660–4.

    PubMed  Article  CAS  Google Scholar 

  41. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55.

    PubMed  Article  CAS  Google Scholar 

  42. Long 3rd HJ, Bundy BN, Grendys Jr EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626–33.

    PubMed  Article  CAS  Google Scholar 

  43. Cormio G, Loizzi V, Gissi F, et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology. 2009;77:281–4.

    PubMed  Article  CAS  Google Scholar 

  44. Achilli C, Palaia I, Perniola G, et al. Complete remission after neoadjuvant chemotherapy of an advanced vulvar cancer patient: a case report. J Obstet Gynaecol Res. 2012;38:1036–9.

    PubMed  Article  Google Scholar 

  45. Belotte J, Awonuga AO, Bolinjkar R, et al. Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva. Obstet Gynecol. 2012;120:458–60.

    PubMed  Article  CAS  Google Scholar 

  46. Han SN, Vergote I, Amant F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. Int J Gynecol Cancer. 2012;22:865–8.

    PubMed  Article  Google Scholar 

  47. Shimizu Y, Hasumi K, Masubuchi K. Effective chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) for a patient with inoperable vulvar cancer. Gynecol Oncol. 1990;36:423–7.

    PubMed  Article  CAS  Google Scholar 

  48. Durrant KR, Mangioni C, Lacave AJ, et al. Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG). Gynecol Oncol. 1990;37:359–62.

    PubMed  Article  CAS  Google Scholar 

  49. Wagenaar HC, Colombo N, Vergote I, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group study. European Organization for Research and Treatment of Cancer. Gynecol Oncol. 2001;81:348–54.

    PubMed  Article  CAS  Google Scholar 

  50. Benedetti-Panici P, Greggi S, Scambia G, et al. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol. 1993;50:49–53.

    PubMed  Article  CAS  Google Scholar 

  51. Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecol Oncol. 2006;100:53–7.

    PubMed  Article  CAS  Google Scholar 

  52. Domingues AP, Mota F, Durao M, et al. Neoadjuvant chemotherapy in advanced vulvar cancer. Int J Gynecol Cancer. 2010;20:294–8.

    PubMed  Article  Google Scholar 

  53. •• Aragona AM, Cuneo N, Soderini AH, et al. Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study. Int J Gynecol Cancer. 2012;22:1258–63. NACT produced a dramatic response rate of more than 80% and the 5-year survival rate following surgery was an impressive 92%.

    PubMed  Article  Google Scholar 

  54. Bellati F, Angioli R, Manci N, et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol. 2005;96:227–31.

    PubMed  Article  CAS  Google Scholar 

  55. Horowitz NS, Olawaiye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012;127:141–6.

    PubMed  Article  CAS  Google Scholar 

  56. Richard SD, Krivak TC, Beriwal S, et al. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer. 2008;18:1132–5.

    PubMed  Article  CAS  Google Scholar 

  57. Alt CD, Brocker KA, Eichbaum M, et al. Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: part 2. Strahlenther Onkol. 2011;187:705–14.

    PubMed  Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Kathryn Graham and Kevin Burton declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Affiliations

  1. Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Great Western Road, Glasgow, G12 0YN, UK

    Kathryn Graham

  2. Department of Gynaecological Oncology, Glasgow Royal Infirmary, Queen Elizabeth Building, 16 Alexandra Parade, Glasgow, G31 2ER, UK

    Kevin Burton

Authors
  1. Kathryn Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn Graham.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Graham, K., Burton, K. “Unresectable” Vulval Cancers: Is Neoadjuvant Chemotherapy the Way Forward?. Curr Oncol Rep 15, 573–580 (2013). https://doi.org/10.1007/s11912-013-0349-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-013-0349-x

Keywords

  • Squamous cell carcinoma
  • Vulva
  • Vulval cancer
  • Surgery
  • Neoadjuvant chemotherapy
  • Chemotherapy
  • Chemoradiotherapy
  • Radiotherapy